Oragenics is focused on the creation of the TerraCoV2 immunization product candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against infectious disease. In addition, Oragenics, Inc. has established an exclusive worldwide channel collaboration with Precigen, Inc., a synthetic biology company. The collaborations allow Oragenics access to Precigen's proprietary technologies toward the goal of accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria.
Oragenics, Inc. was founded in 1996 by Dr. Jeffrey Hillman and Dr. Robert Zahradnik on the concept of Replacement Therapy.
Building Shareholder Value Through Strong Leadership
We are well equipped with a team that is capable of taking our products to the next level.